# Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma

> **NCT07730515** · PHASE1,PHASE2 · RECRUITING · sponsor: **Evopoint Biosciences Inc.** · enrollment: 176 (estimated)

## Conditions studied

- Non-hodgkin Lymphoma
- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** XNW5004 combined with CHOP (incremental)
- **DRUG:** XNW5004 combined with CHOEP (incremental)
- **DRUG:** XNW5004 combined with CHOP (extended)
- **DRUG:** XNW5004 combined with CHOEP (extended)

## Key facts

- **NCT ID:** NCT07730515
- **Lead sponsor:** Evopoint Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730515, "Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*